QNTM (Quantum BioPharma) EPS (Basic) : $-15.23 (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma EPS (Basic)?

Quantum BioPharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-3.53. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-15.23.

Quantum BioPharma's EPS (Diluted) for the three months ended in Mar. 2025 was $-3.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-15.23.

Quantum BioPharma's EPS without NRI for the three months ended in Mar. 2025 was $-2.08. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -13.93.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Quantum BioPharma EPS (Basic) Historical Data

The historical data trend for Quantum BioPharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma EPS (Basic) Chart

Quantum BioPharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-171.60

-65.65

-39.61

-29.93

-13.12

Quantum BioPharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial															-3.43	-5.20	-4.17	-2.33	-3.53

Quantum BioPharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Quantum BioPharma's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-14.203	-	0)	/	1.137
	=	-12.49

Quantum BioPharma's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.577	-	0)	/	2.475
	=	-3.47

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.23

Quantum BioPharma (NAS:QNTM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Quantum BioPharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quantum BioPharma Ltd (NAS:QNTM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

0K91:Germany QNTM:Canada

Address

55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.